microtubule associated protein tau

Overview

Microtubule associated protein tau is a neuronal protein encoded by MAPT that helps stabilize microtubules and supports axonal transport and neuronal maintenance. In the healthy nervous system, tau contributes to cytoskeletal organization and the structural integrity required for normal neuronal function. Its biological importance is underscored by the fact that disruption of tau regulation is strongly associated with tauopathies, a group of neurodegenerative disorders in which tau becomes abnormally modified and accumulates in pathological forms.

In disease contexts, tau is most prominently studied in Alzheimer's disease, where it is a major component of neurofibrillary tangles composed of hyperphosphorylated tau protein. Recent research contexts also emphasize that tau dysfunction can arise from an imbalance between kinases and phosphatases, altered MAPT exon 10 splicing, and the generation of truncated or modified tau species. These changes are linked to neuroinflammation, oxidative stress, neuronal loss, and impaired cognitive function, making tau a central therapeutic target in neurodegeneration.

Focus of Latest Publications

Recent publications consistently frame tau as a key target in Alzheimer’s disease and related neurodegenerative mechanisms. One study on therapeutic nanocarriers for 4-allyl pyrocatechol described Alzheimer’s disease as involving beta-amyloid accumulation, tau protein hyperphosphorylation, cholinergic dysfunction, oxidative stress, neuroinflammation, and neuronal loss, highlighting tau as part of the pathological cascade underlying cognitive decline. Another study developed a fractional-order model of Alzheimer’s disease using an Atangana-Baleanu-Caputo operator to capture the spatiotemporal spread of amyloid-beta and tau protein, indicating that tau propagation was treated as a dynamic biomarker process in disease progression.

Tau was also central in a machine learning-driven screening study of multitarget kinase inhibitors for tauopathy-associated neurodegeneration. That work explicitly noted that tauopathies arise when normal tau functions in axonal transport and neuronal maintenance are disrupted by an imbalance between kinases and phosphatases. In the same context, dual-specificity Tyrosine-Regulated Kinase 1A was highlighted as a regulator of MAPT exon 10 splicing and as a kinase that phosphorylates tau at multiple Ser/Thr residues, priming it for further phosphorylation by other kinases. This supports the view that tau pathology is not only a consequence of aggregation, but also of upstream regulatory and post-translational control.

Several studies treated tau as a therapeutic target rather than only a biomarker. A chemical space analysis used a dataset of 5,211 compounds that inhibit tau protein, explicitly identifying tau as a key therapeutic target for Alzheimer’s disease. Another Alzheimer’s-focused study noted that current therapeutic approaches targeting amyloid-β or tau pathology have largely failed to rescue synaptic function, reinforcing the clinical challenge of translating tau-directed strategies into effective disease modification. A separate review of CRISPR-Cas9 and next-generation gene editing strategies listed MAPT among critical genes considered for therapeutic intervention in Alzheimer’s disease, placing tau within broader gene-editing approaches aimed at neurodegenerative pathways.

New tau species were also reported. A translational neurodegeneration study identified and characterized a novel N-terminally truncated and N-alpha-acetylated tau form, named AcMet11-Tau, described as a pathological truncated tau species with functional relevance in Alzheimer’s disease. This adds to the growing recognition that tau pathology involves multiple molecular forms, not just full-length hyperphosphorylated protein.

Outside classical Alzheimer’s research, tau appeared in a cancer-related context where a metagene-based classification study in non-small cell lung cancer noted that a signaling process “in turn modulates Tau protein activity.” While the publication context does not establish a direct therapeutic role for tau in that setting, it indicates that tau-related biology may intersect with broader signaling networks beyond neurodegeneration.

Key Publications

NEWJun The Association Between Alzheimer's Disease-Related Biomarkers And Parkinson's Disease Based On Single-Cell Sequencing Analysis Combined With Mendelian Randomization. (Journal of molecular neuroscience : MN, 2026, PMID 42298115): "SnRNA-seq analysis demonstrated that MAPT (encoding tau) was predominantly expressed in dopaminergic neurons, with differentially expressed genes enriched in PD- and neurodegeneration-related pathways."
Jun Therapeutic Potential of Stearylamine-Conjugated Phenylboronic Acid-Modified Nanocarriers of 4-Allyl Pyrocatechol in Modulating Sialylation and Neuroinflammation in Scopolamine-Induced Cognitive Impairment in the Rat Model. (Molecular pharmaceutics, 2026, PMID 42267754): "It is characterized by the accumulation of beta-amyloid, tau protein hyperphosphorylation, cholinergic dysfunction, oxidative stress, neuroinflammation, and neuronal loss, all of which contribute to the gradual decline in cognitive function."
May Model Validation Pipeline Against Longitudinal Alzheimer's Biomarker Data. (Neuroinformatics, 2026, PMID 42176081): "This study develops a fractional-order model of Alzheimer's disease using a [Formula: see text]-generalized Atangana-Baleanu-Caputo (ABC) operator to capture the spatiotemporal dynamics of amyloid-beta and tau protein spread, coupled with a neuron regeneration mechanism."
May Uncovering the mechanisms of synergistic drug combinations in non-small cell lung cancer through metagene-based classification. (PloS one, 2026, PMID 42118752): "which in turn modulates Tau protein activity."
May Machine Learning-Driven Ensemble Screening of Multitarget Kinase Inhibitors for Tauopathy-Associated Neurodegeneration Using All-Atom and Steered MD Simulations. (ACS chemical neuroscience, 2026, PMID 41995061): "DYRK1A regulates MAPT exon 10 splicing and phosphorylates tau at multiple Ser/Thr residues, priming it for further phosphorylation by other kinases."
May Piezoelectric nanoparticle-driven rhythmic ultrasound neuromodulation for treatment of early-stage Alzheimer's disease. (Biomaterials, 2026, PMID 41389410): "yet current therapeutic approaches targeting amyloid-β or tau pathology have largely failed to rescue synaptic function."
May Constellation Plots in KNIME: An Automated Scaffold-Based Workflow for Interactive Chemical Space Visualization. (Molecular informatics, 2026, PMID 42057585): "we used a dataset of 5,211 compounds that inhibit Tau protein, a key therapeutic target for Alzheimer's disease."
Apr N-terminally acetylated Met11-Tau: a new pathological truncated Tau species with functional relevance in Alzheimer's disease. (Translational neurodegeneration, 2026, PMID 42046086): "The present study identifies and characterizes a novel N-terminally truncated and N-alpha-acetylated form of the Tau protein, named AcMet11-Tau."
Apr The interplay between mitophagy and ferroptosis in Alzheimer's disease: Mechanisms and therapeutic implications. (Journal of Alzheimer's disease : JAD, 2026, PMID 41823685): "Alzheimer's disease (AD) is pathologically characterized by the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein."
Apr CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review. (Acta neurologica Belgica, 2026, PMID 41931258): "...targeting of critical genes such as APOE4, APP, PSEN1, PSEN2, and MAPT..."